Head-To-Head Contrast: Crinetics Pharmaceuticals (NASDAQ:CRNX) and Cronos Group (NASDAQ:CRON)

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Insider & Institutional Ownership

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 7.8% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Crinetics Pharmaceuticals and Cronos Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1	0	8	1	2.90
Cronos Group	1	2	2	0	2.20

Crinetics Pharmaceuticals presently has a consensus price target of $76.13, suggesting a potential upside of 107.03%. Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 12.55%. Given Crinetics Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Cronos Group.

Earnings & Valuation

This table compares Crinetics Pharmaceuticals and Cronos Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70 million	503.51	-$465.32 million	($5.13)	-7.17
Cronos Group	$146.59 million	6.75	-$9.45 million	$0.01	263.00

Cronos Group has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Crinetics Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares Crinetics Pharmaceuticals and Cronos Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Cronos Group	-1.14%	-1.26%	-1.20%

Summary

Cronos Group beats Crinetics Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.